NeOnc Begins Enrollment for Phase 2 Clinical Trial of NEO100-02
NeOnc’s second concurrent Phase 2 clinical study seeks further safety and preliminary evidence of the biological effects of its lead drug candidate, NEO100™, on certain cancers of the brain…
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors NEO212™ completes the initial two…
NeOnc Technologies Completes $18.5 Million Financing
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status New investment and debt conversion…
NeOnc Receives Breakthrough Medical Technology Achievement Award from CIS
LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum (CIF)…
NeOnc Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board
Los Angeles, CA, April 18, 2023 – NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory board as a strategic advisor.…
NeOnc’s CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’
Los Angeles, CA, Chicago, IL, London, UK, April 4, 2023 – NeOnc Technologies Holdings Inc., a clinical-stage medical biotechnology company, announced that its CEO, Thomas Chen, MD, Ph.D., has received…
NeOnc Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors. AnovaOS™ platform to support efficient…